Last reviewed · How we verify
Placebo Part I
Placebo produces no pharmacological effect and serves as an inert control or reference standard in clinical research.
Placebo Part I, marketed by Orion Corporation, Orion Pharma, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Placebo Part I |
|---|---|
| Also known as | iron sucrose injection - Venofer, RCN3028 placebo, Saline, Machkhan Tab. 8/5 mg(or Machkhan Tab. 16/5 mg) |
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is a non-active substance administered in clinical trials to establish baseline efficacy and safety profiles of investigational drugs through comparison. It leverages the placebo effect—the therapeutic benefit arising from patient expectation and clinical context rather than the drug's inherent pharmacological properties. Placebos are essential for blinded, controlled trial designs to isolate true drug effects from psychological and environmental factors.
Approved indications
- Clinical trial control / comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease (PHASE1)
- Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1 (PHASE1, PHASE2)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (PHASE1)
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants (PHASE1)
- A PhaseⅠ Study of HW252001 in Healthy Subjects (PHASE1)
- A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease (PHASE1)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort (PHASE1)
- Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Part I CI brief — competitive landscape report
- Placebo Part I updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI